An investigator initiated, prospective, randomized, controlled study in order to evaluate the effect of anti-thymocyte globulin (Fresenius ATG) on engraftment, graft versus host disease (GVHD) and graft versus leukemia (GVL) effect in haplo-identical allogeneic haematopoietic stem-cell transplantation.

Trial Profile

An investigator initiated, prospective, randomized, controlled study in order to evaluate the effect of anti-thymocyte globulin (Fresenius ATG) on engraftment, graft versus host disease (GVHD) and graft versus leukemia (GVL) effect in haplo-identical allogeneic haematopoietic stem-cell transplantation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2011

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Graft-versus-host disease; Leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2011 Actual end date (1 Sep 2010) added as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Planned end date changed from 1 Jan 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top